Guy Sutton
LightNews LightNews
guyfsutton.bsky.social
Guy Sutton
@guyfsutton.bsky.social
31 followers 150 following 1 posts
Research Entomologist
Rhodes University, South Africa
R, Julia enthusiast, Statistics-nerd
Posts Replies Media Videos
Reposted by Guy Sutton
michelnivard.bsky.social
I am recruiting a PhD student, co-supervised with George Davey-Smith, Gareth Hawkes and Laura Corbin to study trait residualized for known genetic influences, please Apply! gw4biomed.ac.uk/shining-a-li...
Shining a light on the un-common to identify novel health risk-factors - GW4 BioMed MRC DTP
Project Code MRCPHS25Br Nivard Research Theme Population Health Sciences Project Summary Download Summary Complex traits such as body mass index and height are influenced by a mixture of genetic and e...
gw4biomed.ac.uk
September 2, 2024 at 4:03 PM
guyfsutton.bsky.social
Kosmidis and Zeileis provide a new approach for fitting beta regressions on the [0,1] scale, at the expense of one additional parameter.

Link:
arxiv.org/abs/2409.07233

#stats #statsky #biostats
Extended-support beta regression for $[0, 1]$ responses
We introduce the XBX regression model, a continuous mixture of extended-support beta regressions for modeling bounded responses with or without boundary observations. The core building block of...
arxiv.org
September 17, 2024 at 5:27 AM
Reposted by Guy Sutton
statsepi.bsky.social
I’m not a "real" statistician, and you can be one too.

ICYMI:

statsepi.substack.com/p/im-not-a-r...
I’m not a real statistician, and you can be one too
I was strolling around Cork hand-in-hand with Cara on a bright, Irish summer evening.
statsepi.substack.com
September 15, 2024 at 9:54 AM
Reposted by Guy Sutton
meadekrosby.bsky.social
🚨CLIMATE JOB ALERT 🚨

Come join our team! The Climate Impacts Group at the University of Washington has TWO open positions: Director and climate social scientist. Come be a catalyst for climate resilience in the Northwest and beyond!

Learn more and apply today:
The Climate Impacts Group is hiring! | Climate Impacts Group
The Climate Impacts Group is growing our team! We’re currently hiring for the following positions to help us enact our new strategic plan and increase climate resilience in our region. Positions are h...
cig.uw.edu
September 7, 2024 at 10:20 PM
Reposted by Guy Sutton
frodsan.bsky.social
Just added support for multivariate (multiresponse) models to {DHARMa.helpers}, the #rstats package that facilitates checking #Bayesian #brms models with {DHARMa}

pakillo.github.io/DHARMa.helpe...
an example using DHARMa.helpers R package to check a Bayesian model fitted with brms
July 3, 2024 at 7:42 PM
Reposted by Guy Sutton
vincentab.bsky.social
New #Rstats tutorial: How to Interpret Interactions, Polynomials, and Splines with {marginaleffects}
I'd love to get feeback on this one. It's the first draft of what could become one of the "recipe" chapters in the book. marginaleffects.com/vignettes/in...
Marginal Effects Zoo – Interactions, polynomials, and splines
marginaleffects.com
August 2, 2024 at 12:41 PM
Reposted by Guy Sutton
const-ae.bsky.social
Over on mastodon, @teunbrand.bsky.social presented his new package {{gguidance}} to customize your legends and axis in #ggplot: fosstodon.org/@teunbrand/1...

Now you can, for example, easily distinguish groups of discrete labels without facetting!

#rstats
Code screenshot of ``` ggplot(palmerpenguins::penguins, aes(x = interaction(island, species), y = bill_length_mm)) + geom_boxplot() + ggh4x::scale_x_manual(values = c(1:3, 4.5, 6)) + guides(x = gguidance::guide_axis_nested(drop_zero = FALSE)) ``` plus the outcome where the x-axis is grouped by species
September 12, 2024 at 8:02 AM
Reposted by Guy Sutton
scientificdiscovery.dev
A 2nd phase 3 trial on lenacapavir found around a 96% reduction in HIV infections among men, transwomen, transmen; only 2 of 2180 participants contracted HIV.

The trial was stopped early due to the positive results & all participants were offered the drug
www.clinicaltrialsarena.com/news/gileads...
Gilead has unveiled positive topline results from an interim analysis of its Phase III PURPOSE 2 trial showing that its twice-yearly HIV drug lenacapavir outperformed once-daily Truvada (emtricitabine + tenofovir disoproxil fumarate). The trial (NCT04925752) enrolled cis- and transgender men, transgender women, and gender non-binary individuals who have sex with partners assigned male at birth. Half the patients received lenacapavir, and half received Truvada, a once-daily oral HIV medication. There were two HIV cases out of the 2,180 enrolled patients, meaning 99.9% of patients did not acquire HIV. Lenacapavir was 89% more effective than Truvada, and it reduced HIV infections by 96% compared to background HIV incidence (bHIV).
September 13, 2024 at 5:50 AM